Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis through binding to its specific receptors, which mainly occurs to VEGF receptor 2 (VEGFR-2), a kinase insert domain-containing receptor. Therefore, the disruption of VEGFR-2 signaling provides a promising therapeutic approach for the treatment of cancer by inhibiting abnormal or tumorinduced angiogenesis. To explore this potential, we expressed the catalytic domain of VEGFR- 2 (VEGFR-2-CD) as a soluble active kinase in Escherichia coli. The recombinant protein was purified and the VEGFR-2-CD activity was investigated. The obtained VEGFR-2-CD showed autophosphorylation activity and phosphate transfer activity comparable to the commercial enzyme. Furthermore, the IC 50 value of known VEGFR-2 inhibitor was determined using the purified VEGFR-2-CD. These results indicated a possibility for functional and economical VEGFR-2-CD expression in E. coli to use for inhibitor screening.
CITATION STYLE
Wei, J., Cao, X. D., Zhou, S. M., Chen, C., Yu, H. J., Zhou, Y., & Wang, P. (2015). Soluble expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 in Escherichia coli. Journal of Microbiology and Biotechnology, 25(8), 1227–1233. https://doi.org/10.4014/jmb.1503.03073
Mendeley helps you to discover research relevant for your work.